CRDL stock forecast, quote, news & analysis
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease... Show more
Why Cardiol Therapeutics (CRDL) Is Up +39% in the Last 30 Days
Key Takeaways
- CRDL stock surged +39% over the past 30 days, driven by positive Phase II ARCHER trial results publication and strong earnings beat.
- Over the past quarter, shares rose +34%, supported by Phase III MAVERIC trial enrollment milestones and $31 million in financing.
- Key catalysts include clinical progress in recurrent pericarditis and acute myocarditis therapies, analyst buy ratings, and extended cash runway into 2027.
- Broader biotech sector sentiment and positive heart disease treatment data bolstered investor confidence.
- Stock exhibited volatile but upward-trending price movement amid news flow.
Cardiol Therapeutics (CRDL) Company Overview and Market Position
Cardiol Therapeutics Inc. (CRDL) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart diseases. Its lead candidate, CardiolRx™, a proprietary oral cannabidiol formulation, targets inflammasome pathway activation implicated in conditions like recurrent pericarditis and acute myocarditis. The company also advances CRD-38, a subcutaneous injection for heart failure in preclinical stages.
Operating in the competitive cardiovascular biotech sector, Cardiol differentiates through its novel immunomodulatory approach to underserved rare cardiac indications. With Phase III MAVERIC trial underway and positive Phase II ARCHER data, its pipeline progress explains recent stock resilience amid biotech volatility, highlighting strong fundamentals in high-unmet-need areas.
Cardiol Therapeutics (CRDL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CRDL stock climbed from approximately $0.97 (March 6 close) to $1.35 (April 7 close), marking a +39% gain. The movement was volatile yet trend-driven, with sharp rallies around March 26-31 (+22% in days) tied to earnings and trial news, followed by consolidation near $1.35-$1.41.
For the quarter, shares advanced +34% from $1.01 (January 7 close) to $1.35, reflecting steady uptrend punctuated by dips in early March before late-month surge. Trading volume spiked on catalysts, with 52-week range $0.77-$1.59 underscoring upward momentum.
What Drove CRDL Stock Price in the Last 30 Days
The 30-day rally stemmed primarily from robust Q4 2025 earnings on March 30-31, where EPS of -$0.05 beat estimates of -$0.09 by 44%, narrowing losses and affirming operational execution. Year-end update highlighted full funding for MAVERIC trial via $31M raised, extending runway to Q4 2027.
Positive sentiment amplified by ARCHER Phase II publication in ESC Heart Failure (early April context), showing significant left ventricular mass reduction (-9.2g, p=0.0117) in acute myocarditis, validating CardiolRx™ efficacy. Analyst reiterations like HC Wainwright's Buy/$9 target and Canaccord's Buy/$8 fueled buying. Biotech sector tailwinds on inflammation therapies further supported the volatile upswing.
What Drove CRDL Stock Performance Over the Last Quarter
The quarterly +34% gain built on sustained clinical momentum, starting with January 16 bought-deal financing announcement ($13.5M gross, closed $14.85M January 23), bolstering balance sheet post-October 2025 private placement. January 13 MAVERIC Phase III hit 50% enrollment (target ~110 patients across 25+ sites), signaling pivotal progress in recurrent pericarditis.
February 10 ARCHER topline reinforced with ESC publication, linking to MAVERIC via shared mechanisms. Macro biotech recovery, favorable interest rates, and institutional interest in orphan cardiac drugs amplified impact. Cumulative financing and milestones reduced dilution fears, driving outperformance versus broader indices.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds scanning thousands of tickers. These curated bots employ diverse strategies—such as trend-following, mean reversion, or momentum—across various timeframes, with performance metrics like win rate, profit factor, and Sharpe ratio displayed transparently. Selected for recent relevance and strong backtested/live results, they help traders identify opportunities in volatile markets like biotech. Explore the page to deploy or monitor bots tailored to your risk profile and discover data-driven edges in stock analysis and price movement.
CRDL Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor MAVERIC Phase III enrollment completion (expected Q2 2026) and topline data timeline toward NDA submission. Upcoming Q1 earnings (est. May 2026) will detail burn rate post-financing. ARCHER full dataset and potential expansion to heart failure via CRD-38 IND filing are key.
Industry trends in anti-inflammatory cardio therapies, FDA feedback on orphan status, and analyst updates amid biotech M&A activity warrant attention. Macro factors like interest rates impacting funding and sector sentiment, plus risks from trial delays or dilution, remain critical for price movement outlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Momentum Indicator for CRDL turns negative, indicating new downward trend
CRDL saw its Momentum Indicator move below the 0 level on May 26, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 99 similar instances where the indicator turned negative. In of the 99 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
CRDL moved below its 50-day moving average on May 26, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRDL crossed bearishly below the 50-day moving average on May 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CRDL entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDL advanced for three days, in of 224 cases, the price rose further within the following month. The odds of a continued upward trend are .
CRDL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.854) is normal, around the industry mean (144.130). P/E Ratio (0.000) is within average values for comparable stocks, (97.681). CRDL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.601). CRDL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (0.000) is also within normal values, averaging (95.029).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CRDL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric